nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Dexamethasone—psoriatic arthritis	0.1	0.192	CbGbCtD
Afatinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0958	0.183	CbGbCtD
Afatinib—ABCG2—Methotrexate—psoriatic arthritis	0.0807	0.154	CbGbCtD
Afatinib—ABCB1—Betamethasone—psoriatic arthritis	0.0623	0.119	CbGbCtD
Afatinib—ABCB1—Prednisolone—psoriatic arthritis	0.0614	0.117	CbGbCtD
Afatinib—ABCB1—Prednisone—psoriatic arthritis	0.058	0.111	CbGbCtD
Afatinib—ABCB1—Dexamethasone—psoriatic arthritis	0.0362	0.0691	CbGbCtD
Afatinib—ABCB1—Methotrexate—psoriatic arthritis	0.0291	0.0555	CbGbCtD
Afatinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.0107	0.0506	CbGpPWpGaD
Afatinib—Interstitial lung disease—Auranofin—psoriatic arthritis	0.0101	0.0412	CcSEcCtD
Afatinib—Paronychia—Methotrexate—psoriatic arthritis	0.00801	0.0325	CcSEcCtD
Afatinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.00702	0.0331	CbGpPWpGaD
Afatinib—LCK—Atypical NF-kappaB pathway—REL—psoriatic arthritis	0.00697	0.0328	CbGpPWpGaD
Afatinib—IRAK1—JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1—NOD2—psoriatic arthritis	0.00658	0.031	CbGpPWpGaD
Afatinib—IRAK1—activated TAK1 mediates p38 MAPK activation—NOD2—psoriatic arthritis	0.00627	0.0295	CbGpPWpGaD
Afatinib—LCK—IL2 signaling events mediated by STAT5—LTA—psoriatic arthritis	0.00623	0.0293	CbGpPWpGaD
Afatinib—Dermatitis acneiform—Triamcinolone—psoriatic arthritis	0.00616	0.025	CcSEcCtD
Afatinib—Dermatitis acneiform—Methylprednisolone—psoriatic arthritis	0.00615	0.025	CcSEcCtD
Afatinib—Pulmonary toxicity—Methotrexate—psoriatic arthritis	0.00612	0.0249	CcSEcCtD
Afatinib—Dermatitis acneiform—Dexamethasone—psoriatic arthritis	0.00559	0.0227	CcSEcCtD
Afatinib—Dermatitis acneiform—Betamethasone—psoriatic arthritis	0.00559	0.0227	CcSEcCtD
Afatinib—ERBB4—EV release from cardiac cells and their functional effects—TNF—psoriatic arthritis	0.00559	0.0263	CbGpPWpGaD
Afatinib—Blood potassium decreased—Methylprednisolone—psoriatic arthritis	0.00552	0.0224	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Prednisolone—psoriatic arthritis	0.0052	0.0211	CcSEcCtD
Afatinib—Dermatitis acneiform—Prednisone—psoriatic arthritis	0.00487	0.0198	CcSEcCtD
Afatinib—IRAK1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.00446	0.021	CbGpPWpGaD
Afatinib—Blood potassium decreased—Prednisone—psoriatic arthritis	0.00437	0.0178	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Dexamethasone—psoriatic arthritis	0.00434	0.0176	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Betamethasone—psoriatic arthritis	0.00434	0.0176	CcSEcCtD
Afatinib—Weight decreased—Auranofin—psoriatic arthritis	0.00407	0.0165	CcSEcCtD
Afatinib—Stomatitis—Auranofin—psoriatic arthritis	0.00391	0.0159	CcSEcCtD
Afatinib—ERBB2—Leptin signaling pathway—REL—psoriatic arthritis	0.00391	0.0184	CbGpPWpGaD
Afatinib—Conjunctivitis—Auranofin—psoriatic arthritis	0.0039	0.0158	CcSEcCtD
Afatinib—IRAK1—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.00387	0.0182	CbGpPWpGaD
Afatinib—IRAK1—IL-1 signaling pathway—REL—psoriatic arthritis	0.00362	0.017	CbGpPWpGaD
Afatinib—LCK—Inflammatory Response Pathway—TNFRSF1B—psoriatic arthritis	0.00358	0.0168	CbGpPWpGaD
Afatinib—Keratitis—Prednisolone—psoriatic arthritis	0.00353	0.0143	CcSEcCtD
Afatinib—Eye disorder—Auranofin—psoriatic arthritis	0.00337	0.0137	CcSEcCtD
Afatinib—Alopecia—Auranofin—psoriatic arthritis	0.00319	0.0129	CcSEcCtD
Afatinib—IRAK1—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.00316	0.0149	CbGpPWpGaD
Afatinib—Dysgeusia—Auranofin—psoriatic arthritis	0.00307	0.0125	CcSEcCtD
Afatinib—BLK—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00301	0.0142	CbGpPWpGaD
Afatinib—BLK—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.00299	0.0141	CbGpPWpGaD
Afatinib—Keratitis—Dexamethasone—psoriatic arthritis	0.00294	0.012	CcSEcCtD
Afatinib—Keratitis—Betamethasone—psoriatic arthritis	0.00294	0.012	CcSEcCtD
Afatinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.00264	0.0124	CbGpPWpGaD
Afatinib—LCK—Translocation of ZAP-70 to Immunological synapse—HLA-DRB1—psoriatic arthritis	0.00263	0.0124	CbGpPWpGaD
Afatinib—Mucosal inflammation—Methotrexate—psoriatic arthritis	0.00251	0.0102	CcSEcCtD
Afatinib—IRAK1—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.00241	0.0114	CbGpPWpGaD
Afatinib—LCK—Phosphorylation of CD3 and TCR zeta chains—HLA-DRB1—psoriatic arthritis	0.00241	0.0114	CbGpPWpGaD
Afatinib—LCK—Interferon type I signaling pathways—REL—psoriatic arthritis	0.00237	0.0111	CbGpPWpGaD
Afatinib—IRAK1—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.00228	0.0108	CbGpPWpGaD
Afatinib—Dyspepsia—Auranofin—psoriatic arthritis	0.00225	0.00915	CcSEcCtD
Afatinib—Decreased appetite—Auranofin—psoriatic arthritis	0.00223	0.00904	CcSEcCtD
Afatinib—Constipation—Auranofin—psoriatic arthritis	0.00219	0.00889	CcSEcCtD
Afatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00218	0.0103	CbGpPWpGaD
Afatinib—LCK—PD-1 signaling—HLA-DRB1—psoriatic arthritis	0.00216	0.0102	CbGpPWpGaD
Afatinib—ERBB2—Exemestane—Methylprednisolone—psoriatic arthritis	0.00208	0.12	CbGdCrCtD
Afatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00206	0.00969	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00203	0.00955	CbGpPWpGaD
Afatinib—Interstitial lung disease—Methotrexate—psoriatic arthritis	0.00196	0.00797	CcSEcCtD
Afatinib—IRAK1—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.00191	0.009	CbGpPWpGaD
Afatinib—ERBB2—Exemestane—Prednisone—psoriatic arthritis	0.00189	0.109	CbGdCrCtD
Afatinib—ERBB2—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.00188	0.00883	CbGpPWpGaD
Afatinib—ERBB2—Exemestane—Prednisolone—psoriatic arthritis	0.00185	0.106	CbGdCrCtD
Afatinib—ERBB2—B Cell Activation—REL—psoriatic arthritis	0.00182	0.00856	CbGpPWpGaD
Afatinib—Pruritus—Auranofin—psoriatic arthritis	0.00181	0.00736	CcSEcCtD
Afatinib—ERBB2—DAP12 interactions—HLA-C—psoriatic arthritis	0.00181	0.00852	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—REL—psoriatic arthritis	0.00179	0.00844	CbGpPWpGaD
Afatinib—ERBB4—DAP12 interactions—HLA-C—psoriatic arthritis	0.00178	0.00839	CbGpPWpGaD
Afatinib—Dry eye—Dexamethasone—psoriatic arthritis	0.00176	0.00716	CcSEcCtD
Afatinib—Dry eye—Betamethasone—psoriatic arthritis	0.00176	0.00716	CcSEcCtD
Afatinib—Diarrhoea—Auranofin—psoriatic arthritis	0.00175	0.00712	CcSEcCtD
Afatinib—IRAK1—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00173	0.00814	CbGpPWpGaD
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.00173	0.00814	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—REL—psoriatic arthritis	0.00172	0.00811	CbGpPWpGaD
Afatinib—IRAK1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00171	0.00807	CbGpPWpGaD
Afatinib—LCK—IL12-mediated signaling events—IL12B—psoriatic arthritis	0.0017	0.00802	CbGpPWpGaD
Afatinib—IRAK1—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00168	0.00792	CbGpPWpGaD
Afatinib—LCK—Generation of second messenger molecules—HLA-DRB1—psoriatic arthritis	0.00166	0.0078	CbGpPWpGaD
Afatinib—Vomiting—Auranofin—psoriatic arthritis	0.00163	0.00661	CcSEcCtD
Afatinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00162	0.00764	CbGpPWpGaD
Afatinib—Rash—Auranofin—psoriatic arthritis	0.00161	0.00656	CcSEcCtD
Afatinib—Dermatitis—Auranofin—psoriatic arthritis	0.00161	0.00655	CcSEcCtD
Afatinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.0016	0.00751	CbGpPWpGaD
Afatinib—IRAK1—EBV LMP1 signaling—TNF—psoriatic arthritis	0.00158	0.00745	CbGpPWpGaD
Afatinib—DYRK1A—Circadian rythm related genes—NOS2—psoriatic arthritis	0.00157	0.0074	CbGpPWpGaD
Afatinib—BLK—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.00156	0.00733	CbGpPWpGaD
Afatinib—IRAK1—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00153	0.00721	CbGpPWpGaD
Afatinib—Dry skin—Prednisolone—psoriatic arthritis	0.00152	0.00618	CcSEcCtD
Afatinib—Nausea—Auranofin—psoriatic arthritis	0.00152	0.00618	CcSEcCtD
Afatinib—LCK—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00148	0.00697	CbGpPWpGaD
Afatinib—Sepsis—Prednisone—psoriatic arthritis	0.00144	0.00586	CcSEcCtD
Afatinib—IRAK1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00143	0.00672	CbGpPWpGaD
Afatinib—IRAK1—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00138	0.00648	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—MEFV—psoriatic arthritis	0.00137	0.00646	CbGpPWpGaD
Afatinib—LCK—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.00136	0.0064	CbGpPWpGaD
Afatinib—Cystitis noninfective—Methotrexate—psoriatic arthritis	0.00136	0.00551	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—MEFV—psoriatic arthritis	0.00135	0.00637	CbGpPWpGaD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.00135	0.00635	CbGpPWpGaD
Afatinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.00134	0.00546	CcSEcCtD
Afatinib—Cystitis—Methotrexate—psoriatic arthritis	0.00134	0.00545	CcSEcCtD
Afatinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.00129	0.0061	CbGpPWpGaD
Afatinib—Dry skin—Betamethasone—psoriatic arthritis	0.00127	0.00516	CcSEcCtD
Afatinib—Dry skin—Dexamethasone—psoriatic arthritis	0.00127	0.00516	CcSEcCtD
Afatinib—Hypokalaemia—Betamethasone—psoriatic arthritis	0.00126	0.00512	CcSEcCtD
Afatinib—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.00126	0.00512	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—psoriatic arthritis	0.00126	0.0051	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—psoriatic arthritis	0.00126	0.0051	CcSEcCtD
Afatinib—Conjunctivitis—Prednisolone—psoriatic arthritis	0.00124	0.00505	CcSEcCtD
Afatinib—Upper respiratory tract infection—Triamcinolone—psoriatic arthritis	0.00123	0.00498	CcSEcCtD
Afatinib—Sepsis—Methotrexate—psoriatic arthritis	0.00121	0.0049	CcSEcCtD
Afatinib—Infestation—Methylprednisolone—psoriatic arthritis	0.00117	0.00477	CcSEcCtD
Afatinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00117	0.00477	CcSEcCtD
Afatinib—IRAK1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.00115	0.00543	CbGpPWpGaD
Afatinib—Conjunctivitis—Triamcinolone—psoriatic arthritis	0.00114	0.00465	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Methylprednisolone—psoriatic arthritis	0.00113	0.0651	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—psoriatic arthritis	0.00111	0.0641	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—psoriatic arthritis	0.00111	0.0641	CbGdCrCtD
Afatinib—Epistaxis—Triamcinolone—psoriatic arthritis	0.00111	0.00451	CcSEcCtD
Afatinib—Dry skin—Prednisone—psoriatic arthritis	0.00111	0.00449	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—psoriatic arthritis	0.0011	0.00446	CcSEcCtD
Afatinib—Weight decreased—Betamethasone—psoriatic arthritis	0.00108	0.0044	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—psoriatic arthritis	0.00108	0.0044	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Methylprednisolone—psoriatic arthritis	0.00107	0.0618	CbGdCrCtD
Afatinib—ERBB2—DAP12 interactions—HLA-B—psoriatic arthritis	0.00107	0.00504	CbGpPWpGaD
Afatinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.00106	0.00432	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—psoriatic arthritis	0.00106	0.0608	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—psoriatic arthritis	0.00106	0.0608	CbGdCrCtD
Afatinib—ERBB4—DAP12 interactions—HLA-B—psoriatic arthritis	0.00105	0.00496	CbGpPWpGaD
Afatinib—Conjunctivitis—Dexamethasone—psoriatic arthritis	0.00104	0.00422	CcSEcCtD
Afatinib—Conjunctivitis—Betamethasone—psoriatic arthritis	0.00104	0.00422	CcSEcCtD
Afatinib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00104	0.00421	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—psoriatic arthritis	0.00103	0.0595	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—psoriatic arthritis	0.00103	0.0594	CbGdCrCtD
Afatinib—LCK—TCR signaling—HLA-DRB1—psoriatic arthritis	0.00102	0.00478	CbGpPWpGaD
Afatinib—ERBB2—Triamcinolone—Prednisolone—psoriatic arthritis	0.00101	0.058	CbGdCrCtD
Afatinib—LCK—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.001	0.00472	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000995	0.00469	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MEFV—psoriatic arthritis	0.000992	0.00467	CbGpPWpGaD
Afatinib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000986	0.004	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—psoriatic arthritis	0.00098	0.0564	CbGdCrCtD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000959	0.00452	CbGpPWpGaD
Afatinib—ERBB2—Desoximetasone—Prednisolone—psoriatic arthritis	0.000957	0.0551	CbGdCrCtD
Afatinib—LCK—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.000954	0.00449	CbGpPWpGaD
Afatinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00095	0.00386	CcSEcCtD
Afatinib—Weight decreased—Prednisone—psoriatic arthritis	0.000944	0.00383	CcSEcCtD
Afatinib—LCK—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000929	0.00437	CbGpPWpGaD
Afatinib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000924	0.00375	CcSEcCtD
Afatinib—LCK—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00092	0.00433	CbGpPWpGaD
Afatinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000918	0.00373	CcSEcCtD
Afatinib—EGFR—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000917	0.00432	CbGpPWpGaD
Afatinib—LCK—Costimulation by the CD28 family—HLA-DRB1—psoriatic arthritis	0.000907	0.00427	CbGpPWpGaD
Afatinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000907	0.00427	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000906	0.00427	CbGpPWpGaD
Afatinib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000901	0.00366	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—psoriatic arthritis	0.000896	0.00364	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—psoriatic arthritis	0.000896	0.00364	CcSEcCtD
Afatinib—Back pain—Triamcinolone—psoriatic arthritis	0.00089	0.00361	CcSEcCtD
Afatinib—EGFR—B Cell Activation—REL—psoriatic arthritis	0.000879	0.00414	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HLA-C—psoriatic arthritis	0.000874	0.00412	CbGpPWpGaD
Afatinib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000857	0.00403	CbGpPWpGaD
Afatinib—Alopecia—Betamethasone—psoriatic arthritis	0.000847	0.00344	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—psoriatic arthritis	0.000847	0.00344	CcSEcCtD
Afatinib—LCK—B Cell Activation—REL—psoriatic arthritis	0.000847	0.00399	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HLA-C—psoriatic arthritis	0.000843	0.00397	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000841	0.00396	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000836	0.00394	CbGpPWpGaD
Afatinib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000821	0.00333	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.00081	0.00329	CcSEcCtD
Afatinib—Cough—Triamcinolone—psoriatic arthritis	0.000803	0.00326	CcSEcCtD
Afatinib—ERBB2—Immune System—MEFV—psoriatic arthritis	0.000799	0.00376	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MEFV—psoriatic arthritis	0.000787	0.00371	CbGpPWpGaD
Afatinib—Pneumonia—Methotrexate—psoriatic arthritis	0.000782	0.00318	CcSEcCtD
Afatinib—Eye disorder—Prednisone—psoriatic arthritis	0.00078	0.00317	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000778	0.00316	CcSEcCtD
Afatinib—Infestation—Methotrexate—psoriatic arthritis	0.000778	0.00316	CcSEcCtD
Afatinib—ABL1—Innate Immune System—MEFV—psoriatic arthritis	0.000777	0.00366	CbGpPWpGaD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000776	0.00315	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.00077	0.00362	CbGpPWpGaD
Afatinib—LCK—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000766	0.00361	CbGpPWpGaD
Afatinib—Renal failure—Methotrexate—psoriatic arthritis	0.000764	0.0031	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—psoriatic arthritis	0.000758	0.00308	CcSEcCtD
Afatinib—BLK—Immune System—MEFV—psoriatic arthritis	0.000758	0.00357	CbGpPWpGaD
Afatinib—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000756	0.00307	CcSEcCtD
Afatinib—Infection—Triamcinolone—psoriatic arthritis	0.000746	0.00303	CcSEcCtD
Afatinib—Infection—Methylprednisolone—psoriatic arthritis	0.000744	0.00302	CcSEcCtD
Afatinib—Insomnia—Prednisolone—psoriatic arthritis	0.000739	0.003	CcSEcCtD
Afatinib—Alopecia—Prednisone—psoriatic arthritis	0.000738	0.003	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000735	0.00299	CcSEcCtD
Afatinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000735	0.00298	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000733	0.00298	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—REL—psoriatic arthritis	0.000733	0.00345	CbGpPWpGaD
Afatinib—Mental disorder—Prednisone—psoriatic arthritis	0.000732	0.00297	CcSEcCtD
Afatinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000728	0.00296	CcSEcCtD
Afatinib—Malnutrition—Prednisone—psoriatic arthritis	0.000727	0.00295	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—REL—psoriatic arthritis	0.000722	0.0034	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000715	0.00337	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HLA-C—psoriatic arthritis	0.000703	0.00331	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—REL—psoriatic arthritis	0.000695	0.00327	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HLA-C—psoriatic arthritis	0.000692	0.00326	CbGpPWpGaD
Afatinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000689	0.0028	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000684	0.00278	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—psoriatic arthritis	0.000679	0.00276	CcSEcCtD
Afatinib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000678	0.00275	CcSEcCtD
Afatinib—Infection—Betamethasone—psoriatic arthritis	0.000677	0.00275	CcSEcCtD
Afatinib—Infection—Dexamethasone—psoriatic arthritis	0.000677	0.00275	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000675	0.00318	CbGpPWpGaD
Afatinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000669	0.00272	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000668	0.00271	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000668	0.00271	CcSEcCtD
Afatinib—IRAK1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000666	0.00314	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000665	0.00313	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MEFV—psoriatic arthritis	0.000664	0.00312	CbGpPWpGaD
Afatinib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000661	0.00268	CcSEcCtD
Afatinib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00066	0.00268	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000652	0.00265	CcSEcCtD
Afatinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000647	0.00263	CcSEcCtD
Afatinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000646	0.00262	CcSEcCtD
Afatinib—LCK—Innate Immune System—MEFV—psoriatic arthritis	0.000639	0.00301	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000639	0.00301	CbGpPWpGaD
Afatinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.000635	0.00299	CbGpPWpGaD
Afatinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000629	0.00255	CcSEcCtD
Afatinib—Alopecia—Methotrexate—psoriatic arthritis	0.000617	0.0025	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—psoriatic arthritis	0.000616	0.0025	CcSEcCtD
Afatinib—Insomnia—Betamethasone—psoriatic arthritis	0.000616	0.0025	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000615	0.0025	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—psoriatic arthritis	0.000611	0.00248	CcSEcCtD
Afatinib—EGFR—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000608	0.00286	CbGpPWpGaD
Afatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000608	0.00286	CbGpPWpGaD
Afatinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000608	0.00247	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—psoriatic arthritis	0.0006	0.00244	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.0006	0.00244	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000595	0.00242	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000594	0.00241	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000592	0.00241	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000592	0.00241	CcSEcCtD
Afatinib—Infection—Prednisone—psoriatic arthritis	0.000589	0.00239	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000588	0.00239	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000588	0.00239	CcSEcCtD
Afatinib—Back pain—Methotrexate—psoriatic arthritis	0.000588	0.00239	CcSEcCtD
Afatinib—Fatigue—Betamethasone—psoriatic arthritis	0.000587	0.00239	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000587	0.00239	CcSEcCtD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000584	0.00275	CbGpPWpGaD
Afatinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000582	0.00236	CcSEcCtD
Afatinib—IRAK1—Immune System—MEFV—psoriatic arthritis	0.000578	0.00272	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000576	0.00271	CbGpPWpGaD
Afatinib—Skin disorder—Prednisone—psoriatic arthritis	0.000576	0.00234	CcSEcCtD
Afatinib—Dizziness—Prednisolone—psoriatic arthritis	0.00054	0.00219	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000539	0.00219	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000539	0.00219	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000539	0.00219	CcSEcCtD
Afatinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000538	0.00218	CcSEcCtD
Afatinib—Insomnia—Prednisone—psoriatic arthritis	0.000537	0.00218	CcSEcCtD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000536	0.00252	CbGpPWpGaD
Afatinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000531	0.00216	CcSEcCtD
Afatinib—Cough—Methotrexate—psoriatic arthritis	0.00053	0.00215	CcSEcCtD
Afatinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.00053	0.00215	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—psoriatic arthritis	0.000522	0.00212	CcSEcCtD
Afatinib—EGFR—DAP12 interactions—HLA-B—psoriatic arthritis	0.000517	0.00243	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—NOD2—psoriatic arthritis	0.000517	0.00243	CbGpPWpGaD
Afatinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000516	0.00209	CcSEcCtD
Afatinib—Rash—Prednisolone—psoriatic arthritis	0.000515	0.00209	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000514	0.00209	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000514	0.00209	CcSEcCtD
Afatinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000513	0.00208	CcSEcCtD
Afatinib—Fatigue—Prednisone—psoriatic arthritis	0.000512	0.00208	CcSEcCtD
Afatinib—Headache—Prednisolone—psoriatic arthritis	0.000512	0.00208	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—NOD2—psoriatic arthritis	0.000509	0.0024	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HLA-C—psoriatic arthritis	0.000508	0.00239	CbGpPWpGaD
Afatinib—Constipation—Prednisone—psoriatic arthritis	0.000507	0.00206	CcSEcCtD
Afatinib—LCK—DAP12 interactions—HLA-B—psoriatic arthritis	0.000498	0.00235	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000498	0.00234	CbGpPWpGaD
Afatinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000497	0.00202	CcSEcCtD
Afatinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000495	0.00201	CcSEcCtD
Afatinib—Infection—Methotrexate—psoriatic arthritis	0.000493	0.002	CcSEcCtD
Afatinib—Asthenia—Betamethasone—psoriatic arthritis	0.000489	0.00199	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000489	0.00199	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000486	0.00197	CcSEcCtD
Afatinib—Nausea—Prednisolone—psoriatic arthritis	0.000485	0.00197	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000482	0.00196	CcSEcCtD
Afatinib—Pruritus—Betamethasone—psoriatic arthritis	0.000482	0.00196	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000482	0.00196	CcSEcCtD
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000481	0.00226	CbGpPWpGaD
Afatinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000477	0.00194	CcSEcCtD
Afatinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000476	0.00193	CcSEcCtD
Afatinib—Rash—Triamcinolone—psoriatic arthritis	0.000473	0.00192	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000473	0.00192	CcSEcCtD
Afatinib—Rash—Methylprednisolone—psoriatic arthritis	0.000472	0.00192	CcSEcCtD
Afatinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000472	0.00192	CcSEcCtD
Afatinib—Headache—Triamcinolone—psoriatic arthritis	0.00047	0.00191	CcSEcCtD
Afatinib—Headache—Methylprednisolone—psoriatic arthritis	0.000469	0.00191	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000469	0.0019	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000466	0.00189	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000466	0.00189	CcSEcCtD
Afatinib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000463	0.00218	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000453	0.00214	CbGpPWpGaD
Afatinib—ABL1—Immune System—MEFV—psoriatic arthritis	0.000452	0.00213	CbGpPWpGaD
Afatinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000451	0.00183	CcSEcCtD
Afatinib—Dizziness—Betamethasone—psoriatic arthritis	0.000451	0.00183	CcSEcCtD
Afatinib—Insomnia—Methotrexate—psoriatic arthritis	0.000449	0.00182	CcSEcCtD
Afatinib—Nausea—Triamcinolone—psoriatic arthritis	0.000446	0.00181	CcSEcCtD
Afatinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000445	0.00181	CcSEcCtD
Afatinib—ERBB2—Immune System—REL—psoriatic arthritis	0.000445	0.00209	CbGpPWpGaD
Afatinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000442	0.0018	CcSEcCtD
Afatinib—ERBB4—Immune System—REL—psoriatic arthritis	0.000438	0.00206	CbGpPWpGaD
Afatinib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000437	0.00177	CcSEcCtD
Afatinib—Vomiting—Betamethasone—psoriatic arthritis	0.000433	0.00176	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000433	0.00176	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000431	0.00175	CcSEcCtD
Afatinib—Rash—Betamethasone—psoriatic arthritis	0.00043	0.00174	CcSEcCtD
Afatinib—Rash—Dexamethasone—psoriatic arthritis	0.00043	0.00174	CcSEcCtD
Afatinib—LCK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000429	0.00202	CbGpPWpGaD
Afatinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000429	0.00174	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000429	0.00174	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000428	0.00174	CcSEcCtD
Afatinib—Fatigue—Methotrexate—psoriatic arthritis	0.000428	0.00174	CcSEcCtD
Afatinib—Headache—Betamethasone—psoriatic arthritis	0.000427	0.00173	CcSEcCtD
Afatinib—Headache—Dexamethasone—psoriatic arthritis	0.000427	0.00173	CcSEcCtD
Afatinib—Asthenia—Prednisone—psoriatic arthritis	0.000426	0.00173	CcSEcCtD
Afatinib—BLK—Immune System—REL—psoriatic arthritis	0.000421	0.00198	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000421	0.00198	CbGpPWpGaD
Afatinib—Pruritus—Prednisone—psoriatic arthritis	0.00042	0.0017	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—HLA-B—psoriatic arthritis	0.000416	0.00196	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HLA-B—psoriatic arthritis	0.000409	0.00193	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-C—psoriatic arthritis	0.000409	0.00193	CbGpPWpGaD
Afatinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000406	0.00165	CcSEcCtD
Afatinib—Nausea—Dexamethasone—psoriatic arthritis	0.000405	0.00164	CcSEcCtD
Afatinib—Nausea—Betamethasone—psoriatic arthritis	0.000405	0.00164	CcSEcCtD
Afatinib—ERBB4—Immune System—HLA-C—psoriatic arthritis	0.000403	0.0019	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000403	0.0019	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000399	0.00188	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-C—psoriatic arthritis	0.000398	0.00187	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000393	0.00185	CbGpPWpGaD
Afatinib—Dizziness—Prednisone—psoriatic arthritis	0.000392	0.00159	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000392	0.00159	CcSEcCtD
Afatinib—BLK—Immune System—HLA-C—psoriatic arthritis	0.000388	0.00183	CbGpPWpGaD
Afatinib—EGFR—Immune System—MEFV—psoriatic arthritis	0.000386	0.00182	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000378	0.00178	CbGpPWpGaD
Afatinib—Vomiting—Prednisone—psoriatic arthritis	0.000377	0.00153	CcSEcCtD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000375	0.00177	CbGpPWpGaD
Afatinib—Rash—Prednisone—psoriatic arthritis	0.000374	0.00152	CcSEcCtD
Afatinib—Dermatitis—Prednisone—psoriatic arthritis	0.000374	0.00152	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—NOD2—psoriatic arthritis	0.000374	0.00176	CbGpPWpGaD
Afatinib—LCK—Immune System—MEFV—psoriatic arthritis	0.000372	0.00175	CbGpPWpGaD
Afatinib—Headache—Prednisone—psoriatic arthritis	0.000372	0.00151	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—CRP—psoriatic arthritis	0.000367	0.00173	CbGpPWpGaD
Afatinib—PHKG2—Disease—NOS2—psoriatic arthritis	0.000363	0.00171	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CRP—psoriatic arthritis	0.000362	0.0017	CbGpPWpGaD
Afatinib—Asthenia—Methotrexate—psoriatic arthritis	0.000356	0.00144	CcSEcCtD
Afatinib—EGFR—Adaptive Immune System—REL—psoriatic arthritis	0.000354	0.00167	CbGpPWpGaD
Afatinib—Nausea—Prednisone—psoriatic arthritis	0.000352	0.00143	CcSEcCtD
Afatinib—Pruritus—Methotrexate—psoriatic arthritis	0.000351	0.00142	CcSEcCtD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000345	0.00163	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000342	0.00161	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	0.00034	0.0016	CbGpPWpGaD
Afatinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000339	0.00138	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000338	0.00159	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000333	0.00157	CbGpPWpGaD
Afatinib—Dizziness—Methotrexate—psoriatic arthritis	0.000328	0.00133	CcSEcCtD
Afatinib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000327	0.00154	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000326	0.00154	CbGpPWpGaD
Afatinib—IRAK1—Immune System—REL—psoriatic arthritis	0.000322	0.00151	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.00032	0.00151	CbGpPWpGaD
Afatinib—Vomiting—Methotrexate—psoriatic arthritis	0.000315	0.00128	CcSEcCtD
Afatinib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000314	0.00148	CbGpPWpGaD
Afatinib—Rash—Methotrexate—psoriatic arthritis	0.000313	0.00127	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000312	0.00127	CcSEcCtD
Afatinib—Headache—Methotrexate—psoriatic arthritis	0.000311	0.00126	CcSEcCtD
Afatinib—ERBB2—Immune System—NOD2—psoriatic arthritis	0.000301	0.00142	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HLA-B—psoriatic arthritis	0.0003	0.00141	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NOD2—psoriatic arthritis	0.000296	0.0014	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-C—psoriatic arthritis	0.000296	0.00139	CbGpPWpGaD
Afatinib—Nausea—Methotrexate—psoriatic arthritis	0.000295	0.0012	CcSEcCtD
Afatinib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000292	0.00138	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000292	0.00138	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	0.000286	0.00135	CbGpPWpGaD
Afatinib—BLK—Immune System—NOD2—psoriatic arthritis	0.000285	0.00134	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CRP—psoriatic arthritis	0.000266	0.00125	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	0.000254	0.0012	CbGpPWpGaD
Afatinib—ABL1—Immune System—REL—psoriatic arthritis	0.000252	0.00118	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NOD2—psoriatic arthritis	0.00025	0.00118	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-B—psoriatic arthritis	0.000242	0.00114	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NOD2—psoriatic arthritis	0.000241	0.00113	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-B—psoriatic arthritis	0.000238	0.00112	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	0.000235	0.00111	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-C—psoriatic arthritis	0.000232	0.00109	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-B—psoriatic arthritis	0.000229	0.00108	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000228	0.00107	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NOD2—psoriatic arthritis	0.000218	0.00102	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000216	0.00102	CbGpPWpGaD
Afatinib—EGFR—Immune System—REL—psoriatic arthritis	0.000215	0.00101	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CRP—psoriatic arthritis	0.000214	0.00101	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CRP—psoriatic arthritis	0.000211	0.000992	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NOS2—psoriatic arthritis	0.00021	0.000991	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CRP—psoriatic arthritis	0.000208	0.000978	CbGpPWpGaD
Afatinib—LCK—Immune System—REL—psoriatic arthritis	0.000207	0.000976	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-DRB1—psoriatic arthritis	0.000205	0.000965	CbGpPWpGaD
Afatinib—BLK—Immune System—CRP—psoriatic arthritis	0.000203	0.000954	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-DRB1—psoriatic arthritis	0.000202	0.00095	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	0.000201	0.000946	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	0.000199	0.000937	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-C—psoriatic arthritis	0.000198	0.000932	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000195	0.000917	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-DRB1—psoriatic arthritis	0.000194	0.000914	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	0.000194	0.000912	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000193	0.000908	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-C—psoriatic arthritis	0.000191	0.000898	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—psoriatic arthritis	0.000188	0.000886	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000186	0.000875	CbGpPWpGaD
Afatinib—ERBB2—Disease—NOS2—psoriatic arthritis	0.00018	0.000848	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CRP—psoriatic arthritis	0.000178	0.000836	CbGpPWpGaD
Afatinib—ERBB4—Disease—NOS2—psoriatic arthritis	0.000177	0.000835	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-B—psoriatic arthritis	0.000175	0.000824	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NOS2—psoriatic arthritis	0.000173	0.000816	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CRP—psoriatic arthritis	0.000171	0.000806	CbGpPWpGaD
Afatinib—ABL1—Immune System—NOD2—psoriatic arthritis	0.00017	0.000802	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000163	0.000769	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000157	0.000741	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CRP—psoriatic arthritis	0.000155	0.000728	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DRB1—psoriatic arthritis	0.000148	0.000697	CbGpPWpGaD
Afatinib—EGFR—Immune System—NOD2—psoriatic arthritis	0.000145	0.000685	CbGpPWpGaD
Afatinib—LCK—Immune System—NOD2—psoriatic arthritis	0.00014	0.00066	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-B—psoriatic arthritis	0.000137	0.000645	CbGpPWpGaD
Afatinib—ABL1—Immune System—CRP—psoriatic arthritis	0.000121	0.00057	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—psoriatic arthritis	0.000117	0.000551	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	0.000116	0.000546	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—psoriatic arthritis	0.000113	0.000531	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—psoriatic arthritis	0.000107	0.000502	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—psoriatic arthritis	0.000103	0.000487	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—psoriatic arthritis	9.97e-05	0.000469	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	9.9e-05	0.000466	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.82e-05	0.000463	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	9.54e-05	0.000449	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—psoriatic arthritis	9.1e-05	0.000429	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—psoriatic arthritis	8.71e-05	0.00041	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—psoriatic arthritis	8.39e-05	0.000395	CbGpPWpGaD
